Ceftazidime in the treatment of urinary tract infection

References

• Armstrong G. C., Wise R., Brown R. M., Hancox J. Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations. Antimicrob. Agents Chemother. 1981; 20: 3561. Armstrong G. C., Wise R., Brown R. M., Hancox J. Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations. Antimicrob. Agents Chemother. 1981; 20: 356
   PubMed Web of Science ®Google Scholar
• Bodey G. P., Fainstein V., Hinkle A. M. Comparative in vitro study of a new cephalosporin. Antimicrob. Agents Chemother. 1981; 20: 2262. Bodey G. P., Fainstein V., Hinkle A. M. Comparative in vitro study of a new cephalosporin. Antimicrob. Agents Chemother. 1981; 20: 226
   PubMedGoogle Scholar
• Brumfitt W., Hamilton-Miller J. M. T. The susceptibility of nosocomial pathogens to ceftazidime. J. Antimicrob. Chemother. 1981; 8: 153. Brumfitt W., Hamilton-Miller J. M. T. The susceptibility of nosocomial pathogens to ceftazidime. J. Antimicrob. Chemother. 1981; 8: 15
   PubMed Web of Science ®Google Scholar
• Ericsson H. M., Sherris J. C. The agar plate dilution method. Acta Pathol. Microbiol. Scand. (B) 1971, Suppl., 217: 114. Ericsson H. M., Sherris J. C. The agar plate dilution method. Acta Pathol. Microbiol. Scand. (B) 1971, Suppl., 217: 11
   Google Scholar
• Granninger W., Ho I., Francesconi M., Schmidbauer C., Egger T. Treatment of complicated urinary tract infection caused by, Pseudomonas aeruginosa. J. Antimicrob. Chemother. 1981; 8: 3235. Granninger W., Ho I., Francesconi M., Schmidbauer C., Egger T. Treatment of complicated urinary tract infection caused by, Pseudomonas aeruginosa. J. Antimicrob. Chemother. 1981; 8: 323
   Web of Science ®Google Scholar
• Hamilton-Miller J. M. T., Brumfitt W. Activity of ceftazidime (GR 20263) against nosocomially important pathogens. Antimicrob. Agents Chemother. 1981; 19: 10676. Hamilton-Miller J. M. T., Brumfitt W. Activity of ceftazidime (GR 20263) against nosocomially important pathogens. Antimicrob. Agents Chemother. 1981; 19: 1067
   PubMed Web of Science ®Google Scholar
• Harding S. M., Ayrton J., Thornton J. E., Munro A. J., Hogg M. J. GR 20263: pharmacokinetics in normal subjects. Abstract 93, 20th Interscience Conf. Antimicrob. Agents and Chemotherapy. 19807. Harding S. M., Ayrton J., Thornton J. E., Munro A. J., Hogg M. J. GR 20263: pharmacokinetics in normal subjects. Abstract 93, 20th Interscience Conf. Antimicrob. Agents and Chemotherapy. 1980
   Google Scholar
• Harper P. B., Kirby S. M., O'Callaghan C. H. In vitro properties of GR 20263 — a highly active broad-spectrum cephalosporin with antipseudomonal activity. Proc. 11th International Congress of Chemotherapy. Boston 1979; 2698. Harper P. B., Kirby S. M., O'Callaghan C. H. In vitro properties of GR 20263 — a highly active broad-spectrum cephalosporin with antipseudomonal activity. Proc. 11th International Congress of Chemotherapy. Boston 1979; 269
   Google Scholar
• O'Callaghan C. H., Acred P., Harper P. B., Ryan D. M., Kirby S. M., Harding S. M. GR 20263. A new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob. Agents Chemother. 1980; 17: 8769. O'Callaghan C. H., Acred P., Harper P. B., Ryan D. M., Kirby S. M., Harding S. M. GR 20263. A new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob. Agents Chemother. 1980; 17: 876
   PubMed Web of Science ®Google Scholar
• Lennette E. H., Spaulding E. H., Truant J. P. Manual of Clinical Microbiology2nd edit. American Society of Microbiology, BethesdaMd. 197610. Lennette E. H., Spaulding E. H., Truant J. P. Manual of Clinical Microbiology2nd edit. American Society of Microbiology, BethesdaMd. 1976
   Google Scholar
• Lindberg A. A., Nord C.-E., Hellgren M., Sjoberg L. Identification of Gram-negative aerobic fermentors in a clinical bacteriology laboratory. Med. Microbiol. Immunol. (Berl.) 1974; 159: 20111. Lindberg A. A., Nord C.-E., Hellgren M., Sjoberg L. Identification of Gram-negative aerobic fermentors in a clinical bacteriology laboratory. Med. Microbiol. Immunol. (Berl.) 1974; 159: 201
   PubMed Web of Science ®Google Scholar
• Weinstein A. J. The cephalosporins: activity and clinical use. Drugs 1980; 19: 13712. Weinstein A. J. The cephalosporins: activity and clinical use. Drugs 1980; 19: 137
   Google Scholar
• Williams R. J., Williams J. D. The cephalosporin group of antibiotics. Antibiotics and Chemotherapy — Current Topics, R. N. Gruneberg. MTP Press, Lancaster 1980; 63–11213. Williams R. J., Williams J. D. The cephalosporin group of antibiotics. Antibiotics and Chemotherapy — Current Topics, R. N. Gruneberg. MTP Press, Lancaster 1980; 63–112
   Google Scholar
• Wise R., Andrews J. M., Bedford K. A. Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob. Agents Chemother. 1980; 17: 88414. Wise R., Andrews J. M., Bedford K. A. Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob. Agents Chemother. 1980; 17: 884
   PubMed Web of Science ®Google Scholar
• Zuccoli P., Ho I., Mergoni M., Melley L. Evaluation of ceftazidime in the treatment of severe infection. J. Antimicrob. Chemother. 1981; 8: 31115. Zuccoli P., Ho I., Mergoni M., Melley L. Evaluation of ceftazidime in the treatment of severe infection. J. Antimicrob. Chemother. 1981; 8: 311
   PubMed Web of Science ®Google Scholar